Peninsula biotech lines up chance to crack the peanut allergy nut

After asking U.S. regulators to approve its peanut-desensitizing treatment and completing a late-stage trial in Europe, Aimmune Therapeutics Inc. is poised to bring to market the first broadly effective drug to help peanut allergy patients fend off accidental exposures. Eventually. Although potential competitors — and new avenues for treatment — are months or years behind it, the Brisbane company (NASDAQ: AIMT) may not win U.S. approval until early next year because of the 12-month drug review…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news